Page 197 - 2019_06-Haematologica-web

Predicting cancer-associated venous thromboembolism
Table 2. Studies with relevant characteristics.
Author (year)
Abdel-Razeq (2017)25 Ades (2015)26
Austin (2017)27
Ayyappan (2016)28 Bezan-Graz (2017)10 Bezan-Zurich (2017)10 Borchmann (2016)29 Cella (2017)30
Ferroni (2015)31
Ferroni (2012)32
Fuentes (2017)33
George (2011)34,35 Guadagni (2017)36 Kearney (2009)37 Khorana (2017)38 Khorana (2014)39 Khorana-cohort 2 (2008)7 Kim (2012)40
Kruger (2017)41 Kuderer (2017)42
Kuk (2017)43 Kunapareddy (2017)44 Lim (2015)45
Lubberts (2016)46 Lustig (2015)47 Mandala (2012)9 Mansfield (2016)48 Misch (2013)49
Moore (2011)50 Munoz-Martin (2018)51 Munoz-Martin (2014)52 Noble (2015)53,54 Panizo (2015)55 Papaxoinis56
Park (2017)57
Patel (2015)58
Pelzer (2013)24,59 Petitto (2017)60
Posch (2016)61
Ramos (2016)62
Ruch (2012)63 Rupa-Matysek (2018)64 Rupa-Matysek (2018)65 Santi (2017)66
Sohal (2016)67
Srikanthan cohort 1 (2015)68 Srikanthan cohort 2 (2015)68
Type
Article
Article Abstract Abstract Article Article Abstract Article Article Article Article Article Article Abstract Article Article Article Article Article Article Article Abstract Article Article Article Article Article Article Article Article Article Article Article Article Article Article Article Abstract Article Article Abstract Article Article Article Abstract Article Article
Study Newly VTE design‡ diagnosed screening
cancer only before study start
Cancer type
Various
Colorectal Various DLBCL Testicular Testicular HL Various Various Lung Gastric Various Gastrointestinal Various Various Various Various Various Pancreatic Lung
Ovarian Various DLBCL Testicular Various Various Lung Glioma Various Various Pancreatic Lung Various Gastrointestinal Gastric Prostate Pancreatic Various
Various Urothelial Pancreatic DLBCL Lung
NHL Colorectal Testicular Testicular
Median follow up duration (months)
Study Total population* follow up:
patients with VTE, n (%)
1,677 96 (5.7%)
151 35 (23.2%) 740 72 (9.7%) 241 45 (18.7%) 586 30 (5.1%) 303 21 (6.9%) 5,409 169 (3.1%) 827 52 (6.3%) 810 54 (6.7%) 108 16 (14.8%) 108 9 (8.3%)
1,553 53 (3.4%) 342 32 (9.4%) 112 23 (20.5%)
48 10 (20.8%)
35 8 (22.9%) 1,365 28 (2.1%) 90 15 (16.7%)
111 16 (14.4%) 1,780 111 (6.2%) 57 5 (8.8%)
191 25 (13.1%) 322 29 (9.0%) 72 4 (5.6%) 580 35 (6.0%) 1,412 56 (4.0%) 658 79 (12.0%) 38 4 (10.5%)
932 168 (18.0%) 389 71 (18.3%) 73 22 (30.1%)
1,068 69 (6.5%) 841 43 (5.1%) 526 49 (9.3%) 241 23 (9.5%) 948 58 (6.1%) 144 21 (14.6%) 553 28 (5.1%) 1,594 127 (8.0%) 943 89 (9.4%)
85 19 (22.4%) 428 64 (15.0%) 118 20 ((16.9%)
1,189 15 (1.3%) 1,593 86 (5.4%) 207 20 (9.7%) 105 10 (9.5%)
First 6 months: patients with VTE, n (%)
83 (4.9%)
15 (9.9%) 64 (8.6%) 29 (12.0%) 27 (4.6%) 21 (6.9%) 158 (2.9%) 38 (4.6%) 43 (5.3%) 14 (13.0%) 4 (3.7%) 53 (3.4%) 24 (7.0%) NR
10 (20.8%) 8 (22.9%) NR NR
11 (9.9%) 111 (6.2%) NR
25 (13.1%) 25 (7.8%) 3 (4.2%) 35 (6.0%) NR
44 (6.7%) NR NR
71 (18.3%) 14 (19.2%) 69 (6.5%) 43 (5.1%) 49 (9.3%) 14 (5.8%) 41 (4.3%) 21 (14.6%) NR
91 (5.7%) 55 (5.8%) NR
35 (8.2%) NR
15 (1.3%) 86 (5.4%) 20 (9.7%) 10 (9.5%)
Retrospective
Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Prospective Prospective Retrospective Retrospective Prospective Retrospective Retrospective Prospective Prospective Prospective Retrospective Retrospective Prospective Retrospective Prospective Retrospective Prospective Prospective Prospective Retrospective Retrospective Retrospective Prospective Retrospective Prospective Prospective Retrospective Prospective Prospective Prospective Prospective Prospective Retrospective Retrospective Retrospective Retrospective Prospective Prospective Retrospective Retrospective
No No
No No NR No Yes No NR No NR No No No NR Yes Yes No Yes No Yes No NR NR Yes No NR No No Yes Yes Yes No No Yes No No No NR No Yes No NR No Yes No Yes No No No No No NR No No No NR No NR No No No Yes NR No No Yes No Yes No Yes No Yes No Yes No No No Yes No NR No Yes No Yes No Yes No NR No Yes No Yes No
40
27.5 12 46 79.2 NR 12 8.3 9.2 6.9 21.3 6 11.0 NR 2.8 3.7 2.4 18.9 9.2 6.0 NR 7.9 41.9 33.0 3.0 2.0 15.2 NR NR 6.0 9.5 6,0 3.0 43.0 10.8 24.0 12.0 6.0 24.0 8.6 8.8 37.0 14.0 6.0 6.0 NR NR
continued on next page
haematologica | 2019; 104(6)
1279